Key takeaways
- The concern is the womb lining: if you have a womb and take oestrogen, you need progestogen to protect the lining. Weight loss injections slow stomach emptying, which may reduce absorption of oral progesterone.
- The evidence is limited: the BMS says there are no data showing the actual effect on oral progestogen, bleeding patterns or endometrial risk. Its advice is cautious and based on expert opinion.
- Non-oral options are not affected: a combined patch or the 52 mg levonorgestrel coil (Mirena) needs no change.
- Review your HRT: your clinician should check your regimen when you start Wegovy or Mounjaro and when your dose increases. Never adjust it yourself.
- Report unexpected bleeding: bleeding that persists, is heavy or is unexpected needs assessment.
Why is progesterone necessary in combined HRT?
When a woman who still has her uterus (womb) takes oestrogen to ease hot flushes, night sweats or brain fog, the oestrogen stimulates the cells lining the womb (the endometrium) to grow and thicken.
Without balance, unopposed oestrogen can cause endometrial hyperplasia, an abnormal thickening of the lining, which increases the long-term risk of endometrial (womb) cancer. Progesterone, or a synthetic progestogen, acts as the counterbalance. It stops excessive cell growth and keeps the lining thin and healthy:
- Sequential (cyclical) HRT: progestogen is taken for 12 to 14 days a month to produce a regular bleed.
- Continuous combined HRT: progestogen is taken daily to keep the lining suppressed and, usually, bleed-free.
Protecting the lining depends on absorbing an adequate dose of progestogen into the bloodstream. That is why anything that could change absorption is worth a conversation. Obesity itself also raises the risk of endometrial hyperplasia and cancer, so sensible endometrial protection matters for this group.
How might Wegovy and Mounjaro interfere with oral progesterone?
GLP-1 medicines (such as semaglutide) and dual GIP and GLP-1 medicines (such as tirzepatide) mimic natural gut hormones. One of their main effects is delayed gastric emptying: food and swallowed medicines leave the stomach more slowly. Nausea, vomiting and diarrhoea are also common when you start or increase a dose.
Because of this, oral hormone medicines, including micronised progesterone capsules such as Utrogestan, may not be absorbed as expected. If less progesterone reaches the bloodstream, the womb lining may not be fully protected from the oestrogen in your HRT.
It is important to be clear about what is and is not known. The BMS notes that the impact of semaglutide and tirzepatide on oral HRT is unknown, and that there are no data showing an effect on oral progestogen dosing, bleeding patterns or endometrial risk. The advice below is a cautious, practical approach based on how these medicines affect the contraceptive pill and on expert opinion.
What does the British Menopause Society guidance recommend?
The BMS published its Tool for clinicians on the use of incretin-based therapies in women using HRT in April 2025. In summary, it suggests the following, depending on the progestogen you use:
| Your progestogen | BMS suggested approach |
|---|
| Combined HRT patch | No change |
|---|
| Levonorgestrel coil (LNG-IUD), within its licensed duration | No change |
|---|
| Oral progesterone or progestogen (for example Utrogestan) | Consider changing to the coil, or temporarily increasing the dose for 4 weeks when you start, and keeping a higher dose for 4 weeks after each dose increase |
|---|
| Vaginal progesterone (used off licence) | No change |
|---|
1. A review of your HRT
The BMS recommends that your current HRT is reviewed while you are using these medicines. Your prescribers should know about both treatments so that nothing is missed.
2. A temporary change to oral progesterone, if you prefer to keep taking it
Where a woman prefers to stay on oral progesterone, the BMS describes a potential approach: temporarily increase the oral dose for 4 weeks after starting the injection, then keep a higher dose for 4 weeks after each dose increase, until you reach a stable dose. There are no data on how much of an increase is needed, so this is based on expert opinion, and the BMS says the uncertainty should be shared with you so you can make an informed decision. The size of any adjustment is a clinical decision. Do not change your dose yourself.
3. Non-oral alternatives
Because the concern relates to absorption in the stomach and gut, non-oral progestogen is not expected to be affected. From a practical point of view, the BMS says a non-oral route would be preferable throughout treatment, because a weight loss injection usually involves several dose increases. The main options are:
- The 52 mg levonorgestrel intrauterine system (Mirena coil): releases progestogen directly into the womb, so it bypasses digestion. It also provides contraception in perimenopause. The BMS describes it as likely the most comprehensive option for endometrial protection in this situation (expert opinion). It is fitted in person by a trained clinician, for example through your GP or a sexual health clinic.
- Combined HRT patches (such as Evorel Conti or Evorel Sequi): deliver oestrogen and progestogen through the skin, avoiding the digestive system.
What about oestrogen, and the contraceptive pill?
Transdermal oestrogen is not affected. If you use an oestrogen patch (such as Evorel, Estraderm or Estradot), a gel (such as Oestrogel) or a spray (such as Lenzetto), your oestrogen absorption does not depend on your stomach, so weight loss injections do not change it. The BMS also prefers transdermal oestrogen for women with overweight or obesity: transdermal oestrogen does not appear to increase the risk of venous thromboembolism (blood clots), whereas oral oestrogen does. If you take oral oestrogen and are starting a weight loss injection, your clinician may suggest switching to a transdermal form.
The combined contraceptive pill is a separate question. In perimenopause you may still need contraception. Tirzepatide can reduce the absorption of the combined pill, and the manufacturer advises using a non-oral method, or adding a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase. Read more about oral contraception and ask your prescriber what suits you.
If you are combining medical weight management with HRT, tell a clinician if you notice any of the following:
- Unscheduled or irregular bleeding: breakthrough bleeding, heavy spotting, or bleeding after sex. Irregular bleeding can happen in the first few months of HRT, but bleeding that persists, is heavy, or starts after a time without bleeding needs assessment. The BMS says it may be sensible to investigate earlier in women at higher risk, including women with obesity.
- Symptoms returning: if hot flushes, night sweats or palpitations come back after starting a weight loss injection, mention it. Nausea or changes in how quickly food and tablets pass through your gut may affect how well oral HRT works.
- A planned dose increase: when your weight loss provider plans to step up your Wegovy or Mounjaro dose, make sure they know your HRT brand and dose so any adjustment can be planned in advance.
Joined-up care with PrivateDoc
Managing more than one prescription needs joined-up clinical thinking. When weight loss and hormone treatment are handled separately by different services, an interaction can be missed. PrivateDoc is a Care Quality Commission (CQC) regulated online clinic offering both medical weight loss and menopause care, and our GMC-registered doctors and independent prescribers look at your health as a whole:
- Checks across your medicines: when you start or change a weight loss treatment, we ask about your HRT so a prescriber can review whether an oral progesterone adjustment or a non-oral option is advisable.
- Menopause specialist consultations: if you are starting HRT or want a review, new HRT patients have a 45-minute online video consultation with an experienced, UK-registered clinician. Treatment plans can include transdermal options such as patches, gels and sprays. See our HRT treatments.
- Support through the patient app: you can message a prescriber to report unexpected bleeding or talk through a dose change.
- Sharing with your GP: with your consent, consultation summaries and treatment updates can be shared with your NHS GP so your record stays complete.
Next step
If you take HRT and are thinking about a weight loss injection, or want your HRT reviewed, start a confidential consultation and a registered UK doctor or prescriber will look at your full picture. Considering weight loss treatment first? Check your weight loss eligibility and mention your HRT in your consultation.
Source: British Menopause Society, Tool for clinicians: Use of incretin-based therapies in women using hormone replacement therapy (HRT), April 2025.
Disclaimer: This article is for general information only and does not replace personalised medical advice. Do not start, stop or change any hormone or weight loss medicine without speaking to a registered healthcare professional.
